# YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

> **NCT00050297** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** YM598

## Key facts

- **NCT ID:** NCT00050297
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** — (—)
- **Last updated:** 2012-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050297, "YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00050297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*